Home Menu

Site Navigation



NeuroTalk Support Groups > > >

A promising new approach to blocking Abeta toxicity

 
 
Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 02-16-2016, 09:36 AM #3
kiwi33's Avatar
kiwi33 kiwi33 is offline
Grand Magnate
  
Join Date: Jan 2015
Location: Sydney, Australia.
Posts: 3,093
10 yr Member
kiwi33 kiwi33 is offline
Grand Magnate
kiwi33's Avatar
 
Join Date: Jan 2015
Location: Sydney, Australia.
Posts: 3,093
10 yr Member
Default
Dave, it does indeed look interesting.

One good thing is that bexarotene has FDA approval as a cancer chemotherapeutic which means that the basic (Phase 1 clinical trials) checking will have been done.

So, with luck and more work (if it checks out) it might be possible to introduce it as an AD treatment fairly soon.
__________________
Knowledge is power.
kiwi33 is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
EnglishDave (02-16-2016)
 

« Previous Thread | Next Thread »

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Similar Threads
Thread Thread Starter Forum Replies Last Post
...a promising therapeutic approach for Parkinson's disease GerryW Parkinson's Disease 1 11-12-2015 08:05 AM
New approach promising against multiple sclerosis volada Multiple Sclerosis 4 06-10-2008 05:22 AM


All times are GMT -5. The time now is 07:42 AM.


Powered by vBulletin • Copyright ©2000 - 2025, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise (Lite) - vBulletin Mods & Addons Copyright © 2025 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

All posts copyright their original authors.

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.

Always consult your doctor before trying anything you read here.

Home